Skip to main content
SpringerLink
Log in

Canadian Practical Guide for the Treatment and Management of Atopic Dermatitis

  • Published:
Journal of Cutaneous Medicine and Surgery

Abstract

Background

Atopic dermatitis is a common condition, with a lifetime prevalence of approximately 10% to 20% among the Canadian population. A clear, practical, Canadian guideline for the management of these patients has been lacking.

Objective

To provide primary-care physicians, pediatricians and dermatologists with the first practical and comprehensive set of Canadian recommendations for the management of atopic dermatitis.

Methods

A group of Canadian dermatologists convened to review the current issues of diagnosis, treatment and international guidelines and adapt them to the Canadian context. The reviewers used the latest clinical trial data on atopic dermatitis, complemented by clinical experience, to develop the consensus recommendations found in this review.

Results

In the present report, following a brief review of the epidemiology of and clinical diagnosis criteria for atopic dermatitis, the recommendations for treatment and management are detailed. These recommendations, which are intended to provide clinicians with a useful and valuable tool to help manage their patients with atopic dermatitis, are divided into the following sections: epidemiology, diagnosis, general measures/skin care, acute management of atopic dermatitis, long-term management/disease control, adjunct therapies, and considerations for switching between anti-inflammatory therapies/handling treatment failure.

General measures discussed include hydration with bathing and the use of moisturizers. Management strategies discussed include topical corticosteroids, topical calcineurin inhibitors, antihistamines and anti-infectives.

A management algorithm is also presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution
FIGURE 1
FIGURE 2

Similar content being viewed by others

References

  1. Ellis C, Luger T, Abeck D, et al International Consensus Conference on Atopic Dermatitis II (ICCAD II) clinical update and current treatment strategies. Br J Dermatol 2003; 148(Suppl 63):3–10

    PubMed  Google Scholar 

  2. Boguniewicz M, Leung D. Atopic Dermatitis. In: Middleton E, et al Allergy, Principles and Practice, 5th Ed., Mosby, St. Louis, p. 1123. 1998

  3. Hanifin JM. Epidemiology of Atopic Dermatitis. Immunol Allergy Clin NA 2002; 22:1–24

    Google Scholar 

  4. Graham-Brown RA. Atopic dermatitis: predictions, expectations, and outcomes. J Am Acad Dermatol 2001; 45(1 Suppl):S61–3

    CAS  PubMed  Google Scholar 

  5. Leung DY. Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol 1997; 107(Suppl 1):25–30

    CAS  PubMed  Google Scholar 

  6. Eczema Prevalence in Canada. Ipsos-Insight Health, 2003

  7. Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994;131(3):383–96

    CAS  PubMed  Google Scholar 

  8. Williams HC, Burney PG, Strachan D, et al. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol. 1994 Sep; 131(3):397–405

    CAS  PubMed  Google Scholar 

  9. Williams HC, Burney PG, Pembroke AC, et al. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 1994; 131(3):406–16

    CAS  PubMed  Google Scholar 

  10. Correale CE, Walker C, Murphy L, et al. Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician 1999; 60(4): 1191–8, 1209–10

    CAS  PubMed  Google Scholar 

  11. Bergmann RL, Edenharter G, Bergmann KE, et al. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin Exp Allergy 1998; 28(8):965–70

    CAS  PubMed  Google Scholar 

  12. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001; 44(1 Suppl):S1–S12

    CAS  PubMed  Google Scholar 

  13. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4(37):1–191

    CAS  Google Scholar 

  14. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141(2):264–73

    Article  CAS  PubMed  Google Scholar 

  15. Zuberbier T, Chong SU, Grunow K, et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor: of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001; 108(2):275–80

    Article  CAS  PubMed  Google Scholar 

  16. Kapp A, Bingham A, Folster-Holst R, et al. Pimecromlimu (Elidel® SDZ ASM 981) cream 1%: a new approach to long-term management of atopic dermatitis in infants 3–23 months of age. J Eur Acad Dermatol Venereol 2001; 15(suppl.2)

  17. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001; 144(4):781–7

    CAS  PubMed  Google Scholar 

  18. Van Leent EJM, Graeber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Br J Dermatol 2001; 143:1–8

    Google Scholar 

  19. European Study Group, Graeber M, Hedgecock S, et al. SDZ ASM 981 cream: an emerging new drug for the treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 1998; 11(suppl.2):S198

    Google Scholar 

  20. Van Leent EJM, Ebelin ME, Burtin P, et al. Low systemic concentrations of SDZ ASM 981 after topical treatment of extensive atopic dermatitis lesions. J Eur Acad Dermatol Venereol 1998; 11(suppl.2):133–4

    Google Scholar 

  21. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981)—preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20(4):233–41

    CAS  PubMed  Google Scholar 

  22. Billich A, Aschauer H, Stuetz A. Pimecrolimus permeates less through the skin than corticosteroids and tacrolimus. J Invest Dermatol 2002; 119:346(abstract 831)

    Google Scholar 

  23. Pariser D, Paller A, Langley R, et al. Efficacy and local tolerability of pimecrolimus cream 1% in the treatment of atopic dermatitis in the face/neck region of pediatric subjects. J Invest Dermatol 2002; 119:348(Abstract 845)

    Google Scholar 

  24. Ho V, Halbert A, Takaoka R, et al. Pimecrolimus (Elidel, SDZ ASM 981) Cream 1% is effective and safe in infants aged 3–23 months with atopic dermatitis. J Pediat 2003; 142:155–62

    CAS  PubMed  Google Scholar 

  25. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46(4):495–504

    Article  PubMed  Google Scholar 

  26. Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002; 205(3):271–7

    Article  CAS  PubMed  Google Scholar 

  27. Wahn U, Bos JD, Goodfield M, et al. Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children. Pediatrics 2002; 110:e1

    PubMed  Google Scholar 

  28. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110(2):277–84

    Article  CAS  PubMed  Google Scholar 

  29. Nakagawa H, Etoh T, Ishibashi Y, et al. Tacrolimus ointmen for atopic dermatitis. Lancet 1994; 344(8926):883

    Article  CAS  Google Scholar 

  30. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337(12):816–21

    Article  CAS  PubMed  Google Scholar 

  31. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44(1 Suppl):S58–64

    CAS  PubMed  Google Scholar 

  32. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol. 2000; 136(8):999–1006

    CAS  PubMed  Google Scholar 

  33. Paller AS. Use of nonsteroidal topical immunomodulators for the treatment of atopic eczema in the pediatric population. J Pediatr 2001; 138:163–8

    CAS  PubMed  Google Scholar 

  34. Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109(3):539–46

    CAS  PubMed  Google Scholar 

  35. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111(3):396–8

    CAS  PubMed  Google Scholar 

  36. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102(4 Pt 1):637–44

    CAS  PubMed  Google Scholar 

  37. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44(1 Suppl):S47–57

    Article  CAS  PubMed  Google Scholar 

  38. Hanifin J, Ho V, Kaufmann R, et al. Pimecrolimus (SDZ ASM 981) cream: Good tolerability in paediatric patients. Ann Dermatol Venereol 2002; 129:1S411

    Google Scholar 

  39. Hoare C, et al. Systematic review of treatments of atopic eczema. Health Technol Assess 2000;4:1–191

    CAS  Google Scholar 

  40. Berth-Jones J, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003;326:1367

    CAS  PubMed  Google Scholar 

  41. Hanifin J, et al. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147:528–37

    CAS  PubMed  Google Scholar 

  42. Van der Meer JB, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol 1999; 140:1114–21

    PubMed  Google Scholar 

  43. Kawashima M, Tango T, Noguchi T, et al. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003; 148(6):1212–21

    CAS  PubMed  Google Scholar 

  44. Diepgen TL. Early Treatment of the Atopic Child Study Group: Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 2002; 13(4):278–86

    PubMed  Google Scholar 

  45. Munday J, Bloomfield R, Goldman M, et al. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. Dermatology 2002; 205(1):40–5

    CAS  PubMed  Google Scholar 

  46. Chunharas A, Wisuthsarewong W, Wananukul S, et al. Therapeutic efficacy and safety of loratadine syrup in childhood atopic dermatitis treated with mometasone furoate 0.1 per cent cream. J Med Assoc Thai 2002; 85(4):482–7

    PubMed  Google Scholar 

  47. Rystedt L, Stranngard IL, Strannegard O. Infections as contributing factors to atopic dermatitis. Allergy 1989; 44(suppl 9):79–83

    PubMed  Google Scholar 

  48. Leung DY. Atopic dermatitis and the immune system: the role of superantigens and bacteria. J Am Acad Dermatol 2001; 45(1):S13–S16

    CAS  PubMed  Google Scholar 

  49. Thomas KS, Armstrong S, Avery A, et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ 2002; 324(7340):768

    CAS  PubMed  Google Scholar 

  50. Reynolds NJ, Franklin V, Gray JC, et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001; 357(9273):2012–6

    CAS  PubMed  Google Scholar 

  51. Kuanprasert N, Herbert O, Barnetson RS. Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine. Australas J Dermatol 2002; 43(2):125–7

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dr. Charles Lynde, 3 Ovida Blvd, L3P 7N8, Markham, Ontario

    Charles Lynde, Kirk Barber, Joel Claveau, David Gratton, Vincent Ho, Bernice Krafchik, Richard Langley, Danielle Marcoux, Eileen Murray & Neil Shear

Authors
  1. Charles Lynde
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kirk Barber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joel Claveau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Gratton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vincent Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bernice Krafchik
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Richard Langley
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Danielle Marcoux
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eileen Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Neil Shear
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles Lynde.

Additional information

Canadian Dermatology Association Annual Meeting, June 2003

Article reprint requests: Dr. Charles Lynde

About this article

Cite this article

Lynde, C., Barber, K., Claveau, J. et al. Canadian Practical Guide for the Treatment and Management of Atopic Dermatitis. J Cutan Med Surg (2005). https://doi.org/10.1007/s10227-005-8080-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s10227-005-8080-3

Keywords

Search

Navigation